Drug updated on 10/21/2024
| Dosage Form | Tablet (oral; 17.7 mg, 26.5 mg) |
| Drug Class | Kinase inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test
Latest News
Summary
- This summary is based on the review of one systematic review(s)/meta-analysis(es). [1]
- In a network meta-analysis of 1,358 patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML), there were no significant differences in overall survival (OS) among midostaurin, quizartinib (VANFLYTA), and sorafenib. The hazard ratio (HR) for OS between midostaurin and quizartinib was 1.00 (95% CI, 0.73-1.36), and between quizartinib and sorafenib was 0.97 (95% CI, 0.51-1.85).
- Quizartinib’s effectiveness in terms of OS was comparable to midostaurin and sorafenib, with no significant differences observed among these three FLT3 inhibitors.
- There is no safety information available in the reviewed documents.
- There is no population types or subgroups information available in the reviewed documents.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Vanflyta (quizartinib) Prescribing Information. | 2024 | Daiichi Sankyo, Inc., Basking Ridge, NJ |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| The impact of different FLT3-inhibitors on overall survival of de novo acute myeloid leukemia: A network meta-analysis | 2024 | Leukemia Research |